Essen Biotech
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | CD123 / CD33Cell therapy | Acute Myeloid Leukemia | |
| Phase 1/2 | Tumor antigen menu (TROP2, MSLN, B7-H3, HER2)Cell therapy | Solid Tumors | |
| Phase 1/2 | Personalized, biomarker-guided allogeneic chimeric antigen receptorCell therapy | Solid Tumors |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
EB-SELECT Single-Target CAR-NK Cells + EB-SELECT Dual-Target CAR-NK CellsPhase 1/2Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate Cancer - Recurrent …
Est. primary completion 2027-12-28 · NCT07410494 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.